REGENXBIO Inc. is a next-generation gene therapy company, developing a new class of personalized therapies based on its proprietary NAV® Technology platform. REGENXBIO is leveraging its proprietary NAV® Technology to develop treatments for central nervous system (CNS) diseases such as Hurler Syndrome (MPS I) and Hunter Syndrome (MPS II), as well as other diseases in which gene therapy can make a meaningful difference in patients’ lives.